Kura Oncology (KURA) Revenue & Revenue Breakdown
Kura Oncology Revenue Highlights
Latest Revenue (Y)
$53.88M
Latest Revenue (Q)
$14.11M
Kura Oncology Revenue by Period
Kura Oncology Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $53.88M | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2008-12-31 | - | - |
Kura Oncology generated $53.88M in revenue during NA 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Kura Oncology Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $14.11M | -73.82% |
| 2024-12-31 | $53.88M | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $1.27M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $2.44M | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | - |
Kura Oncology generated $14.11M in revenue during Q1 2025, up -73.82% compared to the previous quarter, and up 1110.87% compared to the same period a year ago.
Kura Oncology Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals | $423.24M | $137.78M |
| DAWN | Day One Biopharmaceuticals | $131.16M | $29.21M |
| GLUE | Monte Rosa Therapeutics | $75.62M | $60.65M |
| ZNTL | Zentalis Pharmaceuticals | $67.42M | $26.86M |
| KURA | Kura Oncology | $53.88M | $14.11M |
| MRUS | Merus | $36.13M | $9.14M |
| SNDX | Syndax Pharmaceuticals | $23.68M | $20.04M |
| CRNX | Crinetics Pharmaceuticals | $1.04M | - |
| DSGN | Design Therapeutics | - | - |
| PTGX | Protagonist Therapeutics | - | $170.64M |
| COGT | Cogent Biosciences | - | - |
| KALV | KalVista Pharmaceuticals | - | - |
| VRDN | Viridian Therapeutics | - | $72.00K |
| REPL | Replimune Group | - | - |
| INZY | Inozyme Pharma | - | - |
| ERAS | Erasca | - | - |
| LRMR | Larimar Therapeutics | - | - |